VivoSeq
Other

Complication

212

Pipeline Programs↗

53

Active Trials↗

70

Companies Involved↗

Complication is a highly competitive landscape with 212 programs across 70 companies. The most active players are NextCell Pharma Ab, Amring, Translational Biosciences. 42 therapies are approved with 49 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

39/100

Mech. Concentration

9/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

NextCell Pharma Ab

1 program

Phase 1A

Amring

1 program

Phase 1T

Translational Biosciences

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1K

Kythera Biopharmaceuticals

1 program

Phase 1M

MaaT Pharma

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical76

Ticagrelor

AstraZeneca

Naloxone

Scienture

Fentanyl

Cephalon

Bevacizumab

Bio-Thera Solutions

Sodium Bicarbonate

Abbott

Phase 113

Prednisone

Roxane Laboratories

Infliximab

Organon and Co

Tranexamic Acid

Amring

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cefazolin

Baxter Healthcare Corporation

Phase 232

Bortezomib

Shilpa Grover, MD, MPH

Ropivacaine

Fresenius Kabi Oncology Ltd.

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Everolimus

Novartis

Colchicine

Alnylam Pharmaceuticals

Phase 349

Istradefylline

Kyowa Kirin Co., Ltd.

Dexamethasone

Aspen Global Incorporated

Metformin

EMD Serono

Acetaminophen

Kenvue Brands

Ketamine

Aultman Health Foundation

Approved42

Propofol

Fresenius Kabi Oncology Ltd.

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Desflurane

Baxter Healthcare Corporation

Dapagliflozin

AstraZeneca

Ferric Carboxymaltose

American Regent, Inc.

Analysis

Modality Breakdown

93%

Small molecule

231 of 249 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody52%Peptide42%Protein / enzyme31%Cell therapy31%Vaccine31%

Small molecule leads; the ring shows all 249 classified programs, each share of the total. Modality classified for 100% of 287 pipeline programs.

Analysis

Trial Status

288

clinical trials

Completed142 · 49%
Unknown status55 · 19%
Recruiting33 · 11%
Terminated23 · 8%
Withdrawn13 · 5%
Not yet recruiting11 · 4%
Other11 · 4%

Clinical Trials

Trial Activity

288 trials

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Recruiting·UUniversity Hospital, Brest·Phase 3·NCT05198960·1,308 enrolled
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
Recruiting·UUniversity of Oklahoma·Phase 2·NCT06488781·787 enrolled
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients at High Risk of Postoperative Pulmonary Complications
Recruiting·—·N/A·NCT06865040·266 enrolled
Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)
Recruiting·SSt. Antonius Hospital·Phase 4·NCT05774691·1,000 enrolled
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Recruiting·CCerevance·Phase 3·NCT06553027·330 enrolled
Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04840693·540 enrolled
Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
Recruiting·WWroclaw Medical University·N/A·NCT07157475·300 enrolled
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
Recruiting·—·Phase 1·NCT07375290·20 enrolled
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Recruiting·EEmory University·Phase 1·NCT06914999·20 enrolled
Efficacy of Angiography With Indocyanine Green in the Identification of Complications After Breast Surgery
Recruiting·UUniversity Hospital A Coruña·N/A·NCT05910931·221 enrolled
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Recruiting·JJiangxi Qingfeng Pharmaceutical Co. Ltd.·Phase 3·NCT06573008·328 enrolled
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Recruiting·RRadboud University Medical Center·Phase 3·NCT05865743·854 enrolled
To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications
Recruiting·ZZhang XIao Mei·Phase 4·NCT06467513·102 enrolled
The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery
Recruiting·SSt. Olavs Hospital·Phase 4·NCT06270407·3,000 enrolled
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Recruiting·SWOG Cancer Research Network·Phase 3·NCT06807437·274 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)